Executive Summary
Six federal contracts totaling $351,510,484 in obligations were analyzed for the single-day period of October 24, 2026, all in the general federal stream with zero defense-related awards, so the entire set is civilian: HHS/Indian Health Service, NASA, DOE, Labor, and GSA.
The dominant theme is civilian facilities, research, and administrative/IT services rather than defense procurement, and the highest-materiality award is JAYNES CORPORATION's $96,728,838 firm-fixed-price design-build contract for the ALAMO NAVAJO HEALTH CENTER, though the recipient's public/private status is undisclosed. All six signals are rated neutral with an average strength of 3.0/10, and no award is clearly bullish or bearish on its own. The main watch item is that three of the larger awards (JAYNES, Accenture Federal Services at $45,668,737, and CLEAR LINCS at $41,104,522) show $0 outlays, so realized revenue is unverified, and the record set does not establish any multi-year budget trend.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior General Federal Contracts digest from October 16, 2026.
Investment Signals (5)
- JAYNES CORPORATION wins $96.7M HHS/Indian Health Service design-build award (LOW)▲
JAYNES CORPORATION (Albuquerque, NM) received a firm-fixed-price contract for the ALAMO NAVAJO HEALTH CENTER running 2026-09-01 through 2029-09-26 with $0 outlayed to date. Investment relevance depends on whether JAYNES is publicly traded, which the data does not disclose.
- Accenture Federal Services $45.7M DOE BPA call with $289.3M ceiling (MEDIUM)▲
Accenture Federal Services LLC received a $45,668,737 firm-fixed-price BPA call from DOE Headquarters Procurement Services, with a base-plus-options value of $289,323,851 through 2032-07-27. Outlays are $0, so option exercise and order flow are the key observable catalysts.
- NASA/JPL funding continuity for Caltech: $75.7M lunar drones and $49.7M atmospheric sounding awards (MEDIUM)▲
California Institute of Technology received two NASA JPL cost-plus-fixed-fee awards: $75,729,570 (lunar drones, $22.3M outlayed, through 2028-09-24) and $49,746,788 (AIRS/AMSU/HSB, $41.8M outlayed, through 2027-09-30). Caltech is a nonprofit, so these signal NASA research continuity rather than equity exposure.
- ADAMS AND ASSOCIATES $42.5M Labor award has only 26% of obligation spent and most value contingent on options (MEDIUM)▲
ADAMS AND ASSOCIATES INC (Reno, NV) holds a $42,532,026 obligation against a $124,081,345 base-plus-options ceiling, with $32,364,709 outlayed and an end date of 2026-11-30 (potential 2029-11-30). Most of the potential value depends on option exercise, and the firm is private.
- CLEAR LINCS $41.1M GSA delivery order with $0 outlays and thin scope description (LOW)▲
CLEAR LINCS LLC (Windsor, CO) received a firm-fixed-price GSA PBS delivery order for 'administrative & management support services' with $0 outlayed as of the data, a one-year term ending 2027-08-31, and no disclosed options. Scope detail is minimal and public-market status is unknown.
Risk Flags (3)
- Execution [MEDIUM RISK]▼
Three of the six awards (JAYNES CORPORATION, Accenture Federal Services, CLEAR LINCS) show $0 outlays, so $211.5M of obligations have no verified revenue recognition yet.
- Budget [LOW RISK]▼
The record set is a single day of awards and does not establish agency budget trajectories for HHS, NASA, DOE, Labor, or GSA, so budget direction cannot be assessed from this data.
- Competition [LOW RISK]▼
Competition signals are unknown for five of six awards; only Accenture's DOE BPA call and the Labor and GSA awards are characterized as full-and-open, leaving protest exposure unassessed.
Opportunities (3)
- ◆
Follow-on and option work on the Caltech/JPL NASA awards for lunar drones and atmospheric sounding, given $22.3M and $41.8M already outlayed respectively.
- ◆
Accenture Federal Services expansion within DOE if BPA options are exercised toward the $289.3M ceiling.
- ◆
Additional Indian Health Service facility work following the ALAMO NAVAJO design-build award.
Sector Themes (2)
- ◆
All six contracts are civilian, with the largest exposure in health facilities construction and space science R&D, and none in defense. This reflects a set of non-DOD agency awards rather than a defense demand signal.
- ◆
Accenture Federal Services (DOE, FFP BPA call) and CLEAR LINCS (GSA, FFP delivery order) show fixed-price awards in professional and IT services, which shift cost-overrun risk to contractors.
Watch List (4)
- 👁
{"entity" => "Accenture PLC (Accenture Federal Services)", "reason" => "$45.7M DOE BPA call with $289.3M base-plus-options value and $0 outlays to date.", "trigger" => "First quarterly outlay disclosure and DOE option exercise decisions through 2032-07-27"}
- 👁
{"entity" => "JAYNES CORPORATION", "reason" => "$96.7M IHS design-build award, the largest in the set, with public status undisclosed.", "trigger" => "Confirmation of public listing status and first outlay reporting after 2026-09-01 start"}
- 👁
{"entity" => "California Institute of Technology / NASA JPL", "reason" => "Two NASA awards totaling $125.5M with substantial outlays already reported.", "trigger" => "Option exercises toward $76.7M base-plus-options ceiling and FY2027 NASA budget outcome"}
- 👁
{"entity" => "Civilian construction and space R&D sector", "reason" => "Civilian facilities and science awards dominate this batch; no defense-related awards present.", "trigger" => "FY2027 appropriations and any continuing resolution affecting late-fiscal-year awards"}
Get daily alerts with 5 investment signals, 3 risk alerts, 3 opportunities and full AI analysis of all 6 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: General Federal Contracts
🇺🇸 More from United States
View all →October 17, 2026
All NASA Contracts — October 17, 2026
All NASA Contracts
October 16, 2026
US Pre-Market SEC Filings Roundup — October 16, 2026
US Pre-Market SEC Filings Roundup
October 16, 2026
Big Pharma Approvals — October 16, 2026
Big Pharma Approvals
October 16, 2026
Insider Trading Pulse — October 16, 2026
Insider Trading Pulse